BiotechTube
Home/Pipeline/ERAS-113

ERAS-113

Undisclosed solid tumors

DiscoveryActive

Key Facts

Indication
Undisclosed solid tumors
Phase
Discovery
Status
Active
Company
Erasca

About Erasca

Erasca is a clinical-stage biotech singularly focused on developing therapies to 'erase' cancers driven by the RAS/MAPK pathway, which affects ~5.5 million new patients annually. The company's core strategy is built on its MAPKlamp™ platform, designed to overcome resistance by simultaneously targeting multiple nodes within the pathway. With a deep pipeline of small molecules, degraders, and bispecific antibodies, and led by a founder with a proven track record in precision oncology, Erasca aims to achieve durable pathway suppression and deliver transformative combination regimens.

View full company profile

Therapeutic Areas

OncologyPrecision Oncology

Other Undisclosed solid tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
Multiple ProgramsAktis OncologyDiscovery
BAT5506CompugenPreclinical
Precision DACsPrelude TherapeuticsDiscovery
V2ACT ImmunotherapyGeneluxPhase 1
ATOR-4066Alligator Bioscience ABDiscovery/Preclinical
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical
Albumin Shield™-Enabled OVTheriva BiologicsPreclinical